Arif Dalvi, MD
Neurology · Boynton Beach, FLNPI 1659422632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,755 of the $147,143 with a category attached, or 77.3%. Acadia Pharmaceuticals Inc accounts for 74.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $48,222 and has fallen 63.9% since, to $17,424 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $694.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$110K
- Biogen$15K
- MDD US Operations, LLC$5K
- Insightec,inc$4K
- Abbott$4K
- Eisai Inc.$2K
- plus $6K from 10 others
Across 53 payments — averaging $30,247 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insightec,ltd$1.6M
- Insightec,inc$747
- Medtronic$580
What the payments were for
- Consulting fees$22,55315%
- Speaking & faculty fees$113,75577%
- Travel & lodging$5,4494%
- Food & beverage$5,3864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 104 | $110,025 |
| Biogen | 12 | $14,985 |
| MDD US Operations, LLC | 27 | $5,054 |
| Insightec,inc | 19 | $4,335 |
| Abbott | 13 | $3,992 |
| Eisai Inc. | 2 | $2,311 |
| Acorda Therapeutics, Inc | 1 | $2,275 |
| Sunovion Pharmaceuticals Inc. | 2 | $2,089 |
| Medtronic(2 entities) | 19 | $1,632 |
| Boston Scientific | 2 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| AbbVie | 4 | $69 |
| UCB, Inc. | 2 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$108,107
- Exablate$4,024
- APOKYN$3,600
- Leqembi$2,311
- INBRIJA$2,275
- Proclaim IPG$2,125
- KYNMOBI$2,075
- Infinity DBS Pulse Generators$1,817
- PERCEPT PC BRAINSENSE$408
- GOCOVRI$125
- REXULTI$122
- ACTIVA$115
- Watchman$106
How this compares
$147,143 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 175 | $1,080,141 |
| ApokynApomorphine Hcl | 11 | $281,497 |
| BotoxOnabotulinumtoxina | 52 | $93,338 |
| RytaryCarbidopa/Levodopa | 84 | $83,285 |
| NeuproRotigotine | 52 | $69,578 |
| InbrijaLevodopa | 15 | $51,647 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,296 | $32,946 |
| MyoblocRimabotulinumtoxinb | 20 | $13,710 |
| Rasagiline Mesylate | 33 | $12,793 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 302 | $8,844 |
| Entacapone | 34 | $8,580 |
| Donepezil Hcl | 437 | $5,201 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 176 | $4,296 |
| AmantadineAmantadine Hcl | 76 | $4,013 |
| Primidone | 128 | $3,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $110,025 | $1,080,141175 claims |
| AbbVieBotox | $69 | $93,33852 claims |
| Amneal Pharmaceuticals LLCRytary | $40 | $83,28584 claims |
| UCB, Inc.Neupro | $52 | $69,57852 claims |
| Acorda Therapeutics, IncInbrija | $2,275 | $51,64715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Boynton Beach
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.